<p>在全球市场应对混合经济信号的背景下，亚洲股市表现出韧性，尽管制造业面临持续挑战，中国股市依然上涨。在这种环境下，内部持股比例高的成长型公司尤其吸引人，因为这通常表明对业务的强烈信心。</p>
<h3>亚洲内部持股比例高的十大成长型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>113.4%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Oscotec (KOSDAQ:A039200)</td>
<td>12.7%</td>
<td>104.1%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.7%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>AprilBioLtd (KOSDAQ:A397030)</td>
<td>31%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们快速增长的亚洲内部持股比例高的 615 只股票的完整列表。</p>
<p>下面我们重点介绍几只我们独特筛选器中的最爱。</p>
<h2>美团 (SEHK:3690)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 美团是一家技术驱动的零售公司，在中华人民共和国、香港、澳门、台湾及国际市场运营，市值约为 6480.7 亿港元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其核心本地商业部门，产生了 2646.1 亿人民币的收入，以及其新业务部门，贡献了 958.5 亿人民币。</p>
<p><strong>内部持股比例：</strong> 11.2%</p>
<p><strong>盈利增长预测：</strong> 每年 31.7%。</p>
<p>美团的盈利预计将显著增长，年均增长率为 31.7%，超过香港市场。尽管预测的股本回报率较低，为 18.7%，但该公司的交易价格大幅低于其估计的公允价值。最近的回购总额达到 52.2 亿美元，表明对未来前景的信心，尽管近期内部购买并不显著。预计收入年增长率为 10.9%，超过市场预期，但低于高增长基准。</p>
<ul>
<li>在这里深入了解美团的具体情况，查看我们的详细增长预测报告。</li>
<li>我们精心准备的美团估值报告暗示其股价可能低于预期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/84d82d8f-bc2a-44fe-a39d-d6eae5c1483f/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/84d82d8f-bc2a-44fe-a39d-d6eae5c1483f/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:3690 截至 2025 年 10 月的盈利和收入增长</p>
<h2>一品红制药集团 (SZSE:300723)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 一品红制药集团有限公司，市值为 266.9 亿人民币，涉及制药产品的研发、生产和销售，通过其子公司进行。</p>
<p><strong>运营：</strong> 一品红制药集团有限公司的收入来自制药产品的研发、生产和销售。</p>
<p><strong>内部持股比例：</strong> 19.1%</p>
<p><strong>盈利增长预测：</strong> 每年 99.5%。</p>
<p>一品红制药集团的收入预计将以每年 25.2% 的速度增长，超过中国市场平均 14.1% 的增速，尽管最近面临财务挫折，包括 2025 年上半年 7354 万人民币的净亏损和波动的股价。预计该公司将在三年内实现盈利，超过市场平均增长率，尽管其股本回报率仍然较低，预测为 13.1%。当前的债务水平未能得到经营现金流的良好覆盖。</p>
<ul>
<li>通过阅读我们的分析师估计报告，深入了解一品红制药集团的表现。</li>
<li>我们的一品红制药集团估值报告中的分析暗示其股价相较于估计价值被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7b915a4f-2583-49d4-85ff-04c24c5535b5/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7b915a4f-2583-49d4-85ff-04c24c5535b5/chart/ownership-breakdown"/></p>
<p>SZSE:300723 截至 2025 年 10 月的持股结构</p>
<h2>Phison Electronics (TPEX:8299)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Phison Electronics Corp. 设计、制造并销售闪存控制器和外围系统应用，市值为 1712.9 亿新台币。</p>
<p><strong>运营：</strong> 该公司从其闪存控制芯片设计部门产生收入，金额为 582.4 亿新台币。</p>
<p><strong>内部持股比例：</strong> 10.9%</p>
<p><strong>盈利增长预测：</strong> 每年 25.3%。</p>
<p>尽管 Phison Electronics 的股价波动，但预计盈利和收入年增长率分别为 25.3% 和 18.4%，超过台湾市场平均水平。最近与 RedData 和 Supermicro 的战略合作增强了其针对 AI 和高密度工作负载的存储解决方案组合。然而，该公司的利润率较去年有所下降，而股息仍未得到自由现金流的充分覆盖。内部持股水平显著，但近期缺乏购买活动。</p>
<ul>
<li>点击探索我们在 Phison Electronics 盈利增长报告中的详细发现。</li>
<li>我们的综合估值报告提出 Phison Electronics 的定价可能低于其财务状况所能证明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0971773-7237-44c3-9e80-ab2f47354f0d/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0971773-7237-44c3-9e80-ab2f47354f0d/chart/ownership-breakdown"/></p>
<p>TPEX:8299 截至 2025 年 10 月的持股结构</p>
<h2>关键要点</h2>
<ul>
<li>在这里调查我们 615 家快速增长的亚洲内部持股比例高的公司的完整名单。</li>
<li>想探索一些替代方案？我们发现 19 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>

一品红

<p>亚洲股市在经济信号混杂的情况下展现出韧性，重点关注内部持股比例高的成长型公司。值得注意的公司包括美团、 一品红制药集团和 Phison Electronics，它们均显示出显著的盈利增长预测和内部人士信心。美团的内部持股比例为 11.2%，预计年盈利增长为 31.7%。一品红以 19.1% 的内部持股比例领先，预测增长为 99.5%。Phison Electronics 的内部持股比例为 10.9%，预计盈利增长为 25.3%。尽管面临挑战，这些公司在亚洲市场中反映出强大的潜力</p>

<p>As global markets navigate a landscape of mixed economic signals, Asian equities have shown resilience, with China's stock markets advancing despite ongoing challenges in the manufacturing sector. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.</p>
<div class="lb-trans"><p>在全球市场应对混合经济信号的背景下，亚洲股市表现出韧性，尽管制造业面临持续挑战，中国股市依然上涨。在这种环境下，内部持股比例高的成长型公司尤其吸引人，因为这通常表明对业务的强烈信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Asia</h3>
<div class="lb-trans"><h3>亚洲内部持股比例高的十大成长型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>113.4%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Oscotec (KOSDAQ:A039200)</td>
<td>12.7%</td>
<td>104.1%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.7%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>AprilBioLtd (KOSDAQ:A397030)</td>
<td>31%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>113.4%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Oscotec (KOSDAQ:A039200)</td>
<td>12.7%</td>
<td>104.1%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.7%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>AprilBioLtd (KOSDAQ:A397030)</td>
<td>31%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 615 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们快速增长的亚洲内部持股比例高的 615 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>下面我们重点介绍几只我们独特筛选器中的最爱。</p>
</div><h2>Meituan (SEHK:3690)</h2>
<div class="lb-trans"><h2>美团 (SEHK:3690)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Meituan is a technology-driven retail company operating in the People's Republic of China, Hong Kong, Macao, Taiwan, and internationally with a market cap of approximately HK$648.07 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 美团是一家技术驱动的零售公司，在中华人民共和国、香港、澳门、台湾及国际市场运营，市值约为 6480.7 亿港元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its Core Local Commerce segment, generating CN¥264.61 billion, and its New Initiatives segment, contributing CN¥95.85 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其核心本地商业部门，产生了 2646.1 亿人民币的收入，以及其新业务部门，贡献了 958.5 亿人民币。</p>
</div><p><strong>Insider Ownership:</strong> 11.2%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 11.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 31.7% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 31.7%。</p>
</div><p>Meituan's earnings are expected to grow significantly at 31.7% annually, outpacing the Hong Kong market. Despite a lower Return on Equity forecast of 18.7%, the company trades at a substantial discount to its estimated fair value. Recent buybacks totaling $5.22 billion indicate confidence in future prospects, although insider buying hasn't been substantial recently. Revenue growth is forecasted at 10.9% per year, surpassing market expectations but below high-growth benchmarks.</p>
<div class="lb-trans"><p>美团的盈利预计将显著增长，年均增长率为 31.7%，超过香港市场。尽管预测的股本回报率较低，为 18.7%，但该公司的交易价格大幅低于其估计的公允价值。最近的回购总额达到 52.2 亿美元，表明对未来前景的信心，尽管近期内部购买并不显著。预计收入年增长率为 10.9%，超过市场预期，但低于高增长基准。</p>
</div><ul>
<li>Dive into the specifics of Meituan here with our thorough growth forecast report.</li>
<li>Our expertly prepared valuation report Meituan implies its share price may be lower than expected.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解美团的具体情况，查看我们的详细增长预测报告。</li>
<li>我们精心准备的美团估值报告暗示其股价可能低于预期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/84d82d8f-bc2a-44fe-a39d-d6eae5c1483f/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/84d82d8f-bc2a-44fe-a39d-d6eae5c1483f/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:3690 Earnings and Revenue Growth as at Oct 2025</p>
<div class="lb-trans"><p>SEHK:3690 截至 2025 年 10 月的盈利和收入增长</p>
</div><h2>ApicHope Pharmaceutical Group (SZSE:300723)</h2>
<div class="lb-trans"><h2>一品红制药集团 (SZSE:300723)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> ApicHope Pharmaceutical Group Co., Ltd., with a market cap of CN¥26.69 billion, is involved in the research and development, production, and sale of pharmaceutical drugs through its subsidiaries.</p>
<div class="lb-trans"><p><strong>概述：</strong> 一品红制药集团有限公司，市值为 266.9 亿人民币，涉及制药产品的研发、生产和销售，通过其子公司进行。</p>
</div><p><strong>Operations:</strong> ApicHope Pharmaceutical Group Co., Ltd. generates its revenue from the research, development, production, and sale of pharmaceutical drugs.</p>
<div class="lb-trans"><p><strong>运营：</strong> 一品红制药集团有限公司的收入来自制药产品的研发、生产和销售。</p>
</div><p><strong>Insider Ownership:</strong> 19.1%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 19.1%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 99.5% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 99.5%。</p>
</div><p>ApicHope Pharmaceutical Group's revenue is forecast to grow at 25.2% annually, outpacing the Chinese market average of 14.1%, despite recent financial setbacks including a net loss of CNY 73.54 million for H1 2025 and volatile share prices. The company is expected to become profitable within three years, surpassing average market growth rates, although its Return on Equity remains low at a forecasted 13.1%. Current debt levels are not well covered by operating cash flow.</p>
<div class="lb-trans"><p>一品红制药集团的收入预计将以每年 25.2% 的速度增长，超过中国市场平均 14.1% 的增速，尽管最近面临财务挫折，包括 2025 年上半年 7354 万人民币的净亏损和波动的股价。预计该公司将在三年内实现盈利，超过市场平均增长率，尽管其股本回报率仍然较低，预测为 13.1%。当前的债务水平未能得到经营现金流的良好覆盖。</p>
</div><ul>
<li>Get an in-depth perspective on ApicHope Pharmaceutical Group's performance by reading our analyst estimates report here.</li>
<li>The analysis detailed in our ApicHope Pharmaceutical Group valuation report hints at an inflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的分析师估计报告，深入了解一品红制药集团的表现。</li>
<li>我们的一品红制药集团估值报告中的分析暗示其股价相较于估计价值被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7b915a4f-2583-49d4-85ff-04c24c5535b5/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/7b915a4f-2583-49d4-85ff-04c24c5535b5/chart/ownership-breakdown"/></p>
<p>SZSE:300723 Ownership Breakdown as at Oct 2025</p>
<div class="lb-trans"><p>SZSE:300723 截至 2025 年 10 月的持股结构</p>
</div><h2>Phison Electronics (TPEX:8299)</h2>
<div class="lb-trans"><h2>Phison Electronics (TPEX:8299)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Phison Electronics Corp. designs, manufactures, and sells flash memory controllers and peripheral system applications globally, with a market cap of NT$171.29 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Phison Electronics Corp. 设计、制造并销售闪存控制器和外围系统应用，市值为 1712.9 亿新台币。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its flash memory control chip design segment, amounting to NT$58.24 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司从其闪存控制芯片设计部门产生收入，金额为 582.4 亿新台币。</p>
</div><p><strong>Insider Ownership:</strong> 10.9%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 10.9%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 25.3% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 25.3%。</p>
</div><p>Phison Electronics, despite a volatile share price, is positioned for growth with forecasted earnings and revenue increases of 25.3% and 18.4% annually, respectively, outpacing Taiwan's market averages. Recent strategic partnerships with RedData and Supermicro enhance its storage solutions portfolio for AI and high-density workloads. However, the company's profit margins have declined from last year while dividends remain inadequately covered by free cash flows. Insider ownership levels are significant but lack recent buying activity.</p>
<div class="lb-trans"><p>尽管 Phison Electronics 的股价波动，但预计盈利和收入年增长率分别为 25.3% 和 18.4%，超过台湾市场平均水平。最近与 RedData 和 Supermicro 的战略合作增强了其针对 AI 和高密度工作负载的存储解决方案组合。然而，该公司的利润率较去年有所下降，而股息仍未得到自由现金流的充分覆盖。内部持股水平显著，但近期缺乏购买活动。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Phison Electronics' earnings growth report.</li>
<li>Our comprehensive valuation report raises the possibility that Phison Electronics is priced lower than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 Phison Electronics 盈利增长报告中的详细发现。</li>
<li>我们的综合估值报告提出 Phison Electronics 的定价可能低于其财务状况所能证明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0971773-7237-44c3-9e80-ab2f47354f0d/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/f0971773-7237-44c3-9e80-ab2f47354f0d/chart/ownership-breakdown"/></p>
<p>TPEX:8299 Ownership Breakdown as at Oct 2025</p>
<div class="lb-trans"><p>TPEX:8299 截至 2025 年 10 月的持股结构</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><ul>
<li>Investigate our full lineup of 615 Fast Growing Asian Companies With High Insider Ownership right here.</li>
<li>Want To Explore Some Alternatives? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里调查我们 615 家快速增长的亚洲内部持股比例高的公司的完整名单。</li>
<li>想探索一些替代方案？我们发现 19 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div>

3 只亚洲成长股受到内部人士的强烈信心支持